Profusa, a digital health company specializing in continuous biochemical monitoring, received approval from the Nasdaq Hearings Panel to transfer its stock listing from The Nasdaq Global Market to The Nasdaq Capital Market. This move is conditional on Profusa meeting certain interim milestones and complying with bid price and stockholders' equity requirements by July 6, 2026. The company focuses on innovative biosensors and data platforms for personalized medical data. This transition aims to maintain its Nasdaq listing while it works on meeting financial standards.
TripAdvisor has agreed to sell its European restaurant reservation platform, TheFork, to American Express for $700 million in cash. TheFork generated $232 million in revenue and $28 million in adjusted EBITDA in the past year. This sale supports Trip...
Smart Clerk, an AI-powered bookkeeping platform, has surpassed 6,000 small business users who rely on its tools to simplify bookkeeping and generate tax-ready reports. The platform recently enhanced its connectivity by integrating with financial data...
The sulfuric acid market is projected to grow from $41.23 billion in 2025 to $49.94 billion by 2030 at a CAGR of 3.9%. Growth is driven by rising demand in metal processing, especially for base metals used in construction, electronics, and renewable ...
SpaceX shares have surged above $170 shortly after its IPO, surpassing two of three early analyst price targets. Initial targets ranged from $165 to $190, with the stock closing near $161 on the first day and rising to around $170 by the second day. ...
Tesla has been accused of presenting misleading safety data to European regulators to gain approval for its Full Self-Driving (FSD) system. Independent researchers and Reuters found that Tesla exaggerated its safety claims by using unrealistic assump...
